Susannah Gray Acquires 50,000 Shares of 4D Molecular Therapeutics
Insider Susannah Gray purchased 50,000 shares of 4D Molecular Therapeutics on June 17, 2026.
Key Points
- Susannah Gray bought 50,000 shares of 4D Molecular Therapeutics on June 17, 2026.
- Shares of 4D Molecular Therapeutics traded at $9.66 with a market cap of approximately $505 million.
- Analysts have set a mean price target of $28.22 for the stock, with a 'buy' consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Susannah Gray acquired 50,000 shares of 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT). This insider purchase did not specify a transaction value or average price, but it reflects a notable interest in the company's future prospects.
Insider Buying and Selling at 4D Molecular Therapeutics, Inc.
Several insiders, including Susannah Gray, made significant purchases on June 17, 2026. Charles Theuer, Glenn Sblendorio, John Milligan, Jacob Chacko, and Nancy Miller-Rich each bought 50,000 shares, while John Milligan acquired 75,000 shares. These transactions were not part of a pre-planned trading program.
4D Molecular Therapeutics, Inc. Stock Down 34.2%
Shares of 4D Molecular Therapeutics traded at $9.66. The company has a market capitalization of approximately $505 million and a beta of 2.756, indicating higher volatility compared to the market. The stock's 52-week range spans from $3.68 to $12.34, with a 50-day moving average of $9.43 and a 200-day moving average of $9.24. The company is not currently profitable, with a forward P/E ratio not meaningful due to negative earnings per share.
$FDMT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts remain optimistic about 4D Molecular Therapeutics, with Jefferies assuming coverage with a 'buy' rating and a $21.00 price target on March 30, 2026. HC Wainwright & Co. reiterated their 'buy' rating with a $36.00 target on March 20, 2026, and RBC Capital maintained a 'buy' rating with a $35.00 target on March 19, 2026. The consensus among analysts is a 'buy' rating, with a mean price target of $28.22 across nine opinions.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. is a biotechnology company based in Emeryville, California, specializing in developing adeno-associated virus vectors. These vectors are used in gene therapy applications, with its lead product candidate, 4D-150, targeting retinal vascular diseases. The company also has projects in cystic fibrosis, geographic atrophy, and alpha-1 anti-trypsin deficiency lung disease. Founded in 2013, 4D Molecular Therapeutics collaborates with Otsuka Pharmaceutical Co., Ltd.
Bottom Line
The recent insider purchases by Susannah Gray and other executives at 4D Molecular Therapeutics underscore their confidence in the company's potential. As a late-stage biotech firm, 4D Molecular Therapeutics is focused on innovative gene therapy solutions, which could drive future growth. Investors often track such insider activities for insights, though it's essential to remember that these transactions may not reflect the company's current financial position or future stock performance.
Get 4D Molecular Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $FDMT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.